This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
National Tuberculosis Surveillance System
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), National Center for HIV, STD, and TB Prevention (NCHSTP), Division of Tuberculosis Elimination (DTBE).
Mode of Administration
Currently, individual TB case reports (Report of Verified Case of Tuberculosis, or RVCT) are submitted electronically via the Tuberculosis Information Management System (TIMS), a comprehensive CDC software system for TB surveillance, patient management, and program evaluation.
Survey Sample Design
Since 1953, through the cooperation of State and local health departments, CDC has collected information on the numbers of reported TB cases in the United States.
In January 1993, DTBE implemented an expanded TB surveillance system, which collects additional information for each reported TB case in order to better monitor trends in TB.
Since 1999, data are collected from 59 reporting areas (the 50 States, the District of Columbia, New York City, Puerto Rico, and other jurisdictions in the Pacific and Caribbean).
Primary Survey Content
Number of new tuberculosis (TB) cases, patient management, and program evaluation.
The expanded surveillance system started in 1993 collects additional data to better monitor and target groups at risk for TB disease, to estimate and follow the extent of drug-resistant TB, and to evaluate outcomes of TB cases. The RVCT form for reporting TB cases was revised to collect information on occupation, the initial drug regimen, human immunodeficiency virus (HIV) test results, history of substance abuse and homelessness, and residence in correctional or long-term care facilities at the time of diagnosis. RVCT Follow Up Report-1 was added to collect drug susceptibility results for the initial M. tuberculosis isolate from patients with culture-positive disease. To evaluate the outcomes of TB therapy, RVCT Follow Up Report-2 was added to collect information on the reason and date therapy was stopped, the type of health care provider, sputum culture conversion, the use of directly observed therapy, and the results of drug susceptibility testing for the final M. tuberculosis isolate from patients with culture-positive disease.
U.S. civilian, noninstitutionalized population.
Age, gender, race, country of origin, metropolitan.
National, and States.